Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 16/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2414369 | 0.86 | HDAC1 (0.80) | HDAC1NAMPTHDAC3HDAC2NCOR2 | |
| SCHEMBL28402820 | 0.79 | HDAC1 (1.00) | HDAC1NAMPTHDAC3HDAC2HDAC4 | |
| SCHEMBL28404719 | 0.78 | HDAC1 (1.00) | HDAC1NAMPTHDAC3HDAC2NCOR2 | |
| SCHEMBL2411383 | 0.77 | HDAC1 (0.77) | HDAC1MAPTALDH1A1NPC1POLB | |
| SCHEMBL28902445 | 0.76 | HDAC2 (0.69) | HDAC1MAPTALDH1A1NPC1POLB | |
| SCHEMBL28402859 | 0.76 | HDAC1 (1.00) | HDAC1MAPTNAMPTHDAC3HDAC2 | |
| SCHEMBL28409508 | 0.76 | HDAC1 (0.81) | HDAC1NAMPTHDAC3HDAC2NCOR2 | |
| SCHEMBL28410650 | 0.76 | HDAC1 (1.00) | HDAC1NAMPTHDAC3HDAC2NCOR2 | |
| SCHEMBL31635256 | 0.76 | HDAC1 (0.66) | HDAC1HDAC3HDAC2NCOR2HDAC4 | |
| SCHEMBL2407970 | 0.75 | HDAC1 (0.64) | HDAC1NAMPTHDAC3HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026239-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-27 | — | — | US | disclosed |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-07 | — | — | US | disclosed |
| US-7687525-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-30 | — | — | US | disclosed |
| US-RE40703-E1 | Cell differentiation inducer, benzamide compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-04-28 | — | — | US | disclosed |
| US-20080188489-A1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
| US-7317028-B2 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| US-RE39754-E1 | Benzamide derivatives and pharmaceutical compositions containing same | SCHERING AG (DE) | 2007-07-31 | — | — | US | disclosed |
| EP-1738752-A1 | Pharmaceutical combinations comprising cis-retine acid | Schering Aktiengesellschaft (DE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1641458-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6794392-B1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | SCHERING AKTIENGESELLSCHAFT | 2004-07-29 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1437346-A1 | Benzamide derivatives useful as cell differentiation inducers | Schering AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-0847992-B1 | Benzamide derivatives, useful as cell differentiation inducers | SCHERING AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| US-6174905-B1 | AS CARCINOSTATIC AGENT TO A HEMATOLOGIC MALIGNANCY AND A SOLID CARCINOMA | MITSUI CHEMICALS, INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0847992-A1 | Benzamide derivatives, useful as cell differentiation inducers | Mitsui Chemicals, Inc. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188489-A1 | Cell differentiation inducer | MCL1, MYADM, MYD88 | HDAC1 150/4885MAPT 4780/4885ALDH1A1 312/4885 |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | MCL1, MYADM, PDCD1 | HDAC1 81/4885MAPT 4816/4885ALDH1A1 100/4885 |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | MCL1, MYADM, MYD88 | HDAC1 163/4885MAPT 4774/4885ALDH1A1 296/4885 |
| US-20050054647-A1 | New pharmaceutical combination | VEGFA, INHA, PGF | HDAC1 976/4885MAPT 1405/4885ALDH1A1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.